Navigation Links
DATATRAK International, Inc. Announces First Quarter Results for 2009

Restructuring Plan Yields Positive Results

CLEVELAND, May 13 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the first quarter of 2009.

Revenue for the first quarter of 2009 remained relatively constant at $2,086,000 compared to $2,088,000 in the same period of 2008. Gross profit margin improved to 77% for the three months ended March 31, 2009 compared to 55% for the first three months of 2008. The improvement in the Company's gross margin reflects a 49% reduction in direct costs.

For the three months ended March 31, 2009, DATATRAK's loss from operations was $(787,000) compared to $(2,225,000) in the first quarter of the prior year. The current year first quarter loss of $(787,000) includes $634,000 of severance charges related primarily to the separation of two executive officers of the Company. Selling, general and administrative expenses decreased approximately $1.2 million in the first quarter of 2009 compared to the first quarter of 2008. Excluding severance charges from both comparable periods, DATATRAK's loss from operations would be $(153,000) in the current year first quarter compared to $(2,199,000) in the same period last year. Net loss for the first quarter of 2009 was $(788,000), or $(0.06) per share on both a basic and diluted basis compared to $(2,233,000) in the first quarter of 2008, or $(0.16) per share on both a basic and diluted basis.

"We are very pleased with our first quarter results, which we believe reflect our continuing efforts to optimize our operating structure," commented Laurence P. Birch, Chairman of the Board and interim-Chief Executive Officer of the Company. "Excluding severance charges, our operating loss for the quarter was only $(153,000) compared to an operating loss of $(2,199,000) in last year's first quarter. This marks our second consecutive quarter of reaching nearly break-even results, and we believe this is an important milestone that we look forward to sharing at the DIA show in San Diego next month. Our cash balance has remained relatively constant, decreasing by only $294,000 this quarter compared to a cash decrease of $2.6 million in the first quarter of 2008. The $294,000 decrease includes the payout of approximately $150,000 for severance commitments. While our current severance commitments are significant, we believe building a strong, experienced management team is imperative to positioning the Company for success, and in turn, driving long-term shareholder value."

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. The DATATRAK eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; delisting of the Company's common shares from the NASDAQ Capital Market; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

                    DATATRAK International, Inc. and Subsidiaries
                      Condensed Consolidated Balance Sheet Data

                                       March 31, 2009  December 31, 2008
                                       --------------  -----------------
    Cash and investments                   $2,077,513         $2,372,294
    Restricted cash - current                       -            218,276
    Accounts receivable, net                1,187,661            927,490
    Property & equipment, net                 679,803            785,549
    Deferred tax assets                       136,500            145,400
    Other                                     232,815            198,131
                                              -------            -------
       Total assets                        $4,314,292         $4,647,140
                                           ==========         ==========

    Accounts payable and other current
     liabilities                           $2,008,149         $1,825,735
    Deferred revenue - current              1,103,807          1,053,096
    Long-term liabilities                   1,669,823          1,446,923
    Shareholders' equity                     (467,487)           321,386
                                            ---------            -------
       Total liabilities and
        shareholders' equity               $4,314,292         $4,647,140
                                           ==========         ==========

                 DATATRAK International, Inc. and Subsidiaries
                Condensed Consolidated Statements of Operations

                                          For the Three Months Ended March 31,
                                                2009                2008
                                                ----                ----
    Revenue                                 $2,086,176          $2,088,229
    Direct costs                               473,862             933,879
                                               -------             -------
       Gross profit                          1,612,314           1,154,350

    Selling, general and
     administrative expenses                 1,643,577           2,830,757
    Severance expense                          633,625              25,843
    Depreciation and amortization              121,976             522,426
                                               -------             -------
       Loss from operations                   (786,864)         (2,224,676)

    Interest income                              3,003              59,740
    Interest expense                             4,008              66,567
    Other loss                                       -               1,382
                                                   ---               -----
       Loss before income taxes               (787,869)         (2,232,885)

    Income tax expense                               -                   -
                                                   ---                 ---
       Net loss                              $(787,869)        $(2,232,885)
                                            ==========        ============
         Net loss per share:
              Net loss per share                $(0.06)             $(0.16)
                                               =======             =======
              Weighted-average shares
               outstanding                  13,741,401          13,681,901
                                            ==========          ==========
              Net loss per share                $(0.06)             $(0.16)
                                               =======             =======
              Weighted-average shares
               outstanding                  13,741,401          13,681,901
                                            ==========          ==========

SOURCE DATATRAK International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DATATRAK International Management To Host Conference Call on November 8, 2007 To Discuss Third Quarter and Nine Month Operating Results for 2007
2. DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results
3. DATATRAK International Launches Innovative, Interactive Educational Webcast Series
4. DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference
5. DATATRAK Closes Second Multi-Year Enterprise Agreement with European Clinical Trial Sponsor
6. DATATRAK International Management to Host Conference Call on February 26, 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007
7. DATATRAK International Reports Fourth Quarter and Full Year Results for 2007
8. DATATRAK Announces Restructured Senior Management Team
9. Ease-of-Use and Intuitive Nature of the DATATRAK eClinical(TM) Platform Allows for Further Operational Efficiencies
10. DATATRAK International, Inc. Receives Notice From Nasdaq
11. DATATRAK International Management to Host Conference Call on November 6, 2008 to Discuss Third Quarter and Nine Month Operating Results for 2008
Post Your Comments:
(Date:10/10/2015)... ... October 10, 2015 , ... Isabel Healthcare will participate in the Cerner Health ... the release of the Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel ... that assist healthcare providers and consumers to potentially reduce the chance of error. The ...
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled ... To Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement ... with a celebratory gala on October 1st. , Many of the features of ...
(Date:10/9/2015)... California (PRWEB) , ... October 09, 2015 , ... ... Osteopathic Medicine of the Pacific Associate Dean for Graduate Medical Education J. Michael ... of the Year Award. Finley was selected for his impact on graduate medical ...
(Date:10/9/2015)... Los Angeles, CA (PRWEB) , ... October 09, 2015 , ... ... awareness for breast cancer victims, survivors, and the ongoing effort to find a cure. ... patients another outlet for helping women in need. With their Bra Collection Campaign, Beverly ...
(Date:10/9/2015)... ... October 09, 2015 , ... A new health tool that helps identify if ... online ( ) – just in time for the cold and flu season, ... However, for many in the U.S., the real start of cold/flu season is the ...
Breaking Medicine News(10 mins):
... ... medical journal Osteoporosis International found that women taking AdvaCAL® calcium had the highest bone ... 32 studies involved 3,169 postmenopausal women, 79 skeletal measures and 7 different types of ... ...
... ... Dermatologist settled in Dubai, received the very prestigious ,HIND RATTAN AWARD, this ... Rattan was presented at a ceremony in connection with the yearly International ... Heavy Industries and Public Enterprises, Government of India. Dr. Mehta was awarded ...
... ... IL based management consulting and technology firm, today announced it will merge ... Gold Certified Partner, effective January 1, 2010. Logan Consulting is ... America, Europe and Asia since 1992. Under the new structure, ...
... , ... Omnetics Connector Corporation, the leading manufacturer of miniature high-rel connectors, is utilizing their ... , ... MN (Vocus) January 29, 2010 -- Omnetics Connector Corporation, the leading manufacturer of ...
... ... Vemma Nutrition Company launches Vemma ... or other sports drinks, Vemma THIRST goes beyond hydration by ... minerals, while replenishing the body with necessary electrolytes, specialized carbohydrates ...
... , , Majority of Mississippi ... Jan. 28 The following is a statement by ... Consumer Healthcare Products Association (CHPA): , "Today, the Mississippi ... that, if it becomes law, will greatly limit how cold and ...
Cached Medicine News:
(Date:10/9/2015)... , Schweiz, October 9, 2015 Der ... an Dr.   Yutaka Kondo und Dr.   Junko ... Award   2015 " geht an Dr.   ... --> Der " JCA-Mauvernay Award   2015 ... und Dr.   Junko Takita    ™ , ...
(Date:10/8/2015)... PITTSBURGH , Oct. 8, 2015  Mylan N.V. ... will host a conference call and webcast on Tuesday, ... review the value to be created for shareholders of ... Mylan,s offer to acquire the company. During the call, ... compelling proposition for Perrigo shareholders. Mylan,s offer represents a ...
(Date:10/8/2015)... , Oct. 8, 2015  The National Heart, ... $40 million to the Broad Institute of MIT ... of 20,000 individuals, as well as data to ... profiling. Trans-Omics for Precision Medicine ... toward a larger initiative, which will use whole ...
Breaking Medicine Technology:
... 20 Kinetic Systems, Inc., a leading global provider ... general industry clients, announced today the appointment of Peter ... well as to its Board of Directors. He will ... Mr. Maris has been with Kinetics for ...
... Sept. 20 Accuray Incorporated (Nasdaq: ARAY ), ... that its management is scheduled to present at the JMP ... 28, 2010 at 11:30 a.m. ET/8:30 a.m. PT. ... from the investor relations page of the Company,s Web site ...
Cached Medicine Technology:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: